THALIA THERAPEUTICS PLC - Investor Presentation

In this episode, we explore Thalia Therapeutics PLC innovative approach to tackling aggressive cancers and cardiovascular diseases. They aim to reawaken dormant leukemia stem cells, allowing traditional chemotherapy to effectively target and eliminate them. The company recently acquired a promising drug, now known as Myerstin, focusing on acute myeloid leukemia, and they are working on RNA therapies for cardiovascular risk factors. Thalia's proprietary delivery system, Nuvek, aims to revolutionize treatment compliance by releasing therapies over an extended period. With a recent £2.75 million fundraising for clinical trials, Thalia demonstrates a commitment to operational efficiency in the biotech field, raising intriguing possibilities for the future of RNA therapy in disease management.